Oncolytic viruses and cancer therapy (Q34234147)

31 July 2017

1 reference

title

Oncolytic viruses and cancer therapy (English)

1 reference

31 July 2017

1 reference

Norman KL

1

1 reference

31 July 2017

Farassati F

series ordinal

2

1 reference

31 July 2017

Lee PW

series ordinal

3

1 reference

31 July 2017

language of work or name

1 reference

1 June 2001

1 reference

Cytokine and Growth Factor Reviews

31 July 2017

published in

1 reference

31 July 2017

volume

12

1 reference

31 July 2017

issue

2-3

1 reference

31 July 2017

page(s)

271-282

1 reference

New developments in the virus therapy of cancer: a historical review

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

p53 mutations in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Killing tumor cells with viruses--a question of specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

ONYX-015: clinical data are encouraging

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Replication-selective adenoviruses as oncolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

1 reference

7 January 2021

The preferential cytotoxicity of reovirus for certain transformed cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Enzymatic and control functions of reovirus structural proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Neutralization of reovirus: the gene responsible for the neutralization antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The alpha-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Reovirus binds to multiple plasma membrane proteins of mouse L fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Herpes Simplex Viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Capsid assembly and DNA packaging in herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Conditionally replicating herpes vectors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

A synthetic inhibitor of the mitogen-activated protein kinase cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Farnesyltransferase inhibitors versus Ras inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

PKR; a sentinel kinase for cellular stress

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2800%2900024-1

7 January 2021

10.1016/S1359-6101(00)00024-1

Identifiers

DOI

1 reference

31 July 2017

1 reference